El-Moatasem Gabr

El-Moatasem Gabr

Auto-generated profile, based on publicly available information

El-Moatasem Gabr

Houston Methodist DeBakey Heart & Vascular Center , Houston, TX

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
MMMaan Malahfji
Maan Malahfji
MSMujtaba Saeed
Mujtaba Saeed
DNDuc Nguyen
Duc Nguyen
YKYodying Kaolawanich
Yodying Kaolawanich
HLHossam Lababidi
Hossam Lababidi
DSDipan J. Shah
Dipan J. Shah
Management of patients with combined aortic and mitral regurgitation (AR and MR) is largely based on expert opinion. Specifically, the outcomes of patients with combined moderate AR and moderate MR under medical surveillance are uncertain. This study aimed to evaluate cardiac remodeling using cardiac magnetic resonance (CMR) in patients with combined AR/MR compared with isolated AR, to assess degree of MR associated with adverse outcomes, and evaluate the outcomes of asymptomatic patients with combined moderate AR and moderate MR under medical surveillance. The authors conducted a multicenter observational outcome study of patients with moderate or severe AR on CMR, and evaluated the etiology and degree of concomitant MR in patients with combined AR and MR. They excluded patients if they had prior valvular surgery, > mild valve stenosis, hypertrophic or infiltrative cardiomyopathy, or congenital heart disease except bicuspid aortic valve. The authors evaluated ventricular volumes and function across the spectrum of regurgitation severity. Receiver-operating characteristic analyses for the association of concomitant MR severity with outcomes were performed. The primary outcome was all-cause death. Secondary outcome was all-cause death or heart failure (HF) hospitalization. Patients were censored at the time of valvular surgery or intervention. Propensity score matching was done between isolated AR and the combined AR/MR groups. The authors studied 915 patients with a median age of 61 years (Q1-Q3: 49-72 years), 79.5% male, 29% with bicuspid aortic valve, and a median AR fraction of 38% (Q1-Q3: 32%-45%). In 251 of 915 patients (27.4%) with concomitant MR, the median MR fraction was 24% (Q1-Q3: 17%-35%). The presence of concomitant ≥moderate MR (14.2% of the total population) was associated with a greater increase in ventricular volumes per unit increase in AR severity, and a decline in ventricular function (P for interaction ≤0.01). During a median follow-up of 3.0 years (Q1-Q3: 1.1-5.6 years), there were 152 deaths. Presence of concomitant ≥moderate MR was associated with an increased hazard for all-cause death (HR: 2.77; 95% CI: 1.91-4.01; P < 0.001), and the secondary outcome of death or HF (HR: 2.62; 95% CI: 1.87-3.67; P < 0.001). In asymptomatic or minimally symptomatic patients undergoing medical surveillance, the presence of combined moderate AR and moderate MR was independently associated with a higher hazard for the primary and secondary outcomes compared with isolated AR, independent of age, sex, comorbidities, ejection fraction, and end-systolic volume. Findings were consistent in the propensity matched cohort. The presence of combined AR and MR on CMR is associated with a greater extent of ventricular remodeling and increased hazard for adverse outcomes, compared with isolated AR. Asymptomatic patients with combined moderate AR and MR under medical surveillance are at higher risk for death and HF, and warrant further study.

15 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MHMohamed Hamed
Mohamed Hamed
EGEl‐Moatasem Gabr
El‐Moatasem Gabr
WHWissam Harmouch
Wissam Harmouch
SSShani Scwartz
Shani Scwartz
PHPhillip Habib
Phillip Habib
AEAyman Elbadawi
Ayman Elbadawi
Background: Older adult patients have been underrepresented in the pivotal trials comparing an invasive versus conservative management for non–ST‐segment–elevation myocardial infarction (NSTEMI). Methods: We performed an electronic search of MEDLINE, Embase, and Cochrane databases through September 2024 for randomized controlled trials comparing invasive versus conservative management of NSTEMI in patients aged ≥70 years. Results: The final analysis included 7 randomized controlled trials with 2997 patients. The weighted mean follow‐up time was 47.1 months, and the mean age was 82.6 years. There was no significant difference in all‐cause mortality between an invasive versus a conservative management approach (27.9% versus 26.6%; risk ratio [RR], 1.05 [95% CI, 0.94–1.18]; I 2 =0%). There was a statistically nonsignificant trend for fewer major adverse cardiac events in the invasive group (28.3% versus 33.4%; RR, 0.82 [95% CI, 0.68–1.00]; P =0.05, I 2 =58%). An invasive approach was associated with a lower risk of recurrent myocardial infarction (RR, 0.76 [95% CI, 0.60–0.97]) and ischemia‐driven revascularization (RR, 0.29 [95% CI, 0.21–0.40]) without an increase in major bleeding (RR, 1.31 [95% CI, 0.86–1.97]) compared with a conservative approach. There were no significant differences between both approaches in cardiovascular mortality, acute cerebrovascular events, or length of hospital stay. Conclusions: Among older adult patients with NSTEMI, there was no significant difference in survival between an invasive or a conservative approach. An invasive approach was associated with a lower risk of recurrent myocardial infarction and ischemia‐driven revascularization without an increase in the risk of major bleeding. The findings should help with informed decision‐making among older adult patients with NSTEMI.

1 January 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
MHMohamed Hamed
Mohamed Hamed
SMSheref A. Mohamed
Sheref A. Mohamed
AAAsmaa Ahmed
Asmaa Ahmed
MHMuhammad Adnan Haider
Muhammad Adnan Haider
EGEl-Moatasem Gabr
El-Moatasem Gabr
AEAyman Elbadawi
Ayman Elbadawi

11 June 2026 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
EGEl-Moatasem Gabr
El-Moatasem Gabr
MXMianli Xiao
Mianli Xiao
MSMujtaba Saeed
Mujtaba Saeed
ADAmr Darwish
Amr Darwish
ABAkila Bersali
Akila Bersali
DSDipan J. Shah
Dipan J. Shah
Patients with moderate aortic stenosis (AS) and concomitant mitral regurgitation (MR) often present with symptoms despite neither lesion individually reaching intervention thresholds. The clinical impact of this dual-valvular disease remains a knowledge gap. To evaluate the effect of concomitant MR on cardiac remodeling and clinical outcomes in patients with moderate AS using cardiac magnetic resonance (CMR) and to compare with isolated moderate and severe AS. We studied 742 patients with at least moderate AS on CMR (422 moderate AS, 320 severe AS). Patients were stratified by AS severity and MR burden. Remodeling parameters, symptoms, and outcomes—including cardiovascular (CV) death and heart failure (HF) hospitalization—were analyzed. Multivariable Cox models identified covariates associated with outcomes. Among 422 patients with moderate AS, 76 had ≥moderate MR. Compared with isolated moderate AS, combined AS+MR was associated with higher symptom burden (80.3% NYHA II-IV), more pronounced remodeling (larger indexed LV volumes, lower LVEF), and reduced aortic forward flow. Over a median 1.8 years, coexisting ≥moderate MR was independently associated with CV-death or HF-hospitalization (adjusted HR 1.86, 95% CI 1.31–2.65, p<0.001). This risk was more apparent in the low-flow subgroup (SVi ≤35 mL/m2), whereas in normal-flow patients there was a trend to increased risk that did not reach statistical significance. Outcomes in moderate AS with ≥moderate MR were worse than in isolated severe AS and comparable to severe AS populations meeting criteria for intervention. Patients with moderate AS+MR are a high-risk subgroup with high symptom burden, adverse cardiac remodeling, and poor clinical outcomes. Risk appears more pronounced in the setting of reduced forward flow (SVi ≤35 mL/m2). CMR enables quantitative assessment of dual-valvular burden and may improve risk stratification. These findings highlight a therapeutic gap and support studies of earlier intervention in this high-risk subgroup.

1 July 2026 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
TCTommy Chiou
Tommy Chiou
IMIva Minga
Iva Minga
VSVarun Subashchandran
Varun Subashchandran
CSCristiane C Singulane
Cristiane C Singulane
APAmit R Patel
Amit R Patel
JSJeremy Slivnick
Jeremy Slivnick
Aims: While cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum biomarkers. We evaluated the incremental value of incorporating CMR parameters into the National Amyloidosis Center (NAC) staging and assessed their utility in guiding evaluation for advanced heart failure (HF) therapies and emerging disease-modifying treatments. Methods and Results: We retrospectively analyzed a multicenter cohort of 266 ATTR-CA patients who underwent CMR between 2007-2023. Cox regressions were used to assess time to death. A baseline model was constructed using the NAC stage. CMR predictor variables were selected a priori based on clinical relevance and non-collinearity, then refined using stepwise backward elimination regression with NAC stage control; variables retained in ≥60% of 1,000 bootstrapped samples were included. Internal validation was performed via bootstrapping, with performance reported as Harrell’s C-statistic and calibration slope. Decision curve analysis evaluated clinical utility. 85 patients (32%) died over a median follow up of 20 months (IQR 8-35). Extracellular volume (ECV ≥59%, HR 2.45, 95% CI 1.2-5.2, p = 0.020) and indexed left atrial volume (LAVi ≥54 ml/m2, HR 2.00, 95% CI 1.1–3.7, p = 0.026) were independently associated with mortality after NAC adjustment and improved prognostic accuracy across all biomarker stages. When risk prediction was framed around initiation of advanced HF or emerging disease-modifying therapies, incorporating CMR alongside NAC staging facilitated identification of 28 additional high-risk patients per 1,000. Conclusion: CMR-derived ECV and LAVi were associated with incremental prognostic value in ATTR-CA beyond biomarker staging and may inform clinical risk stratification.

9 July 2026 in JACC: Case Reports
Verified
Journal Article
Open access
EGEl-Moatasem Gabr
El-Moatasem Gabr
AVAravinthan Vignarajah
Aravinthan Vignarajah
GSGautam Shah
Gautam Shah
Mitral valve repair (MVr) can alter left ventricular outflow tract (LVOT) geometry and precipitate dynamic LVOT obstruction (LVOTO) in patients with underlying hypertrophic cardiomyopathy (HCM). Cardiac myosin inhibitors are now a Class I recommendation for symptomatic obstructive HCM, yet their role in post-surgical LVOTO remains undefined. A 66-year-old woman with prior MVr developed progressive symptomatic dynamic LVOTO with resting and Valsalva gradients of 33 and 48 mmHg, systolic anterior motion (SAM), and NYHA class II-III symptoms. Mavacamten produced marked gradient reduction to 7 mmHg at rest and with Valsalva, with SAM resolution and symptomatic improvement to NYHA class II. Dose reduction to 2.5 mg led to gradient recurrence; re-escalation to 5 mg restored suppression, suggesting a reproducible dose-dependent effect. Mavacamten effectively reduced dynamic LVOTO despite surgically altered mitral geometry, expanding the therapeutic scope of myosin inhibition to a post-surgical population not well represented in the major trials. Dynamic LVOTO may emerge or progress after mitral valve repair in patients with underlying hypertrophic cardiomyopathy. Mavacamten may provide effective non-surgical suppression of post-repair dynamic LVOTO despite surgically altered mitral geometry.